Background Despite advances in diagnosis and surgical strategies, up to 70 % of patients will develop recurrence of the disease after resection of colorectal cancer liver metastases (CRCLM). The purpose of our study was to determine the frequency of four different mechanisms of intrahepatic dissemination, and to evaluate the impact of each mechanism on patient outcomes. Methods The medical records of 118 patients who underwent a first resection of CRCLM during the period between 2000 and 2010 were reviewed. Clinicopathologic variables and outcome parameters were examined. Resected specimens were submitted to routine histological evaluation, and immunohistochemical staining with D2-40 (lymphatic vessels), CD34 (blood vessels), CK-7 (biliary epithelium), and CK-20 (CRC cells). Results The mean follow-up after resection was 38 months. Tumor recurrence was observed in 76 patients, with a median interval of 13 months after resection. Overall survival and disease-free survival (DFS) rates after hepatectomy were 62 and 56 %, and 26 and 24 % at 3 and 5 years, respectively. Intrahepatic microscopic invasion included portal venous in 49 patients, sinusoidal in 43 patients, biliary in 20 patients, and lymphatic in 33 patients. Intra-hepatic lymphatic invasion was the only mechanism of dissemination independently associated with the risk of hepatic recurrence (odds ratio 2.75) and shorter DFS (p = 0.006). Conclusion Intrahepatic lymphatic invasion is a significant prognostic factor. Other mechanisms of invasion, although frequently observed, are not related to recurrence or survival, suggesting that the lymphatic system is the main route for dissemination of CRCLM. Furthermore, immunohistochemical detection of intrahepatic lymphatic invasion might be of value in clinical practice.
Introduction
The liver is the most common site of distant metastases in patients with colorectal cancer (CRC). Surgery represents the basis for curative treatment of CRC liver metastases (CRCLM), with long-term survival rates ranging from 36 to 58 % and from 23 to 36 % at 5 and 10 years, respectively [1] [2] [3] [4] [5] [6] . Despite advances in diagnosis, staging, and surgical strategies, 60-70 % of patients will develop recurrence of the disease, even after R0 resection of CRCLM [6, 7] .
In the last few years, the aim of many studies has been to identify biomarkers capable of stratifying CRCLM into prognostic groups. Hereupon, reassessing histomorphological features related to different mechanisms of intrahepatic tumor spread can be of potential clinical value.
The presence of lymphovascular invasion has been shown to be an independent adverse prognostic factor for early recurrence, disease-free survival (DFS), and overall survival (OS) after resection of CRC [8, 9] . Moreover, in stage II patients, it is taken into account when determining if adjuvant therapy should be started.
For CRCLM, the presence of intrahepatic lymphatic, blood vascular, and sinusoidal dissemination has been reported to be associated with an increased risk of intrahepatic recurrence and worse survival after liver resection [10] [11] [12] [13] .
The aims of the present study were to (1) distinguish between intrahepatic lymphatic vascular invasion (LVI), blood vascular invasion (BVI), biliary invasion (Bili), and sinusoidal invasion (SI) in order to determine which type of intrahepatic spread is more frequent; (2) compare the accuracy of the assessment of the different intrahepatic mechanisms of dissemination using routine hematoxylin and eosin (H&E)-stained sections with that obtained from immunohistochemistry (IHC)-stained analysis; and (3) to investigate the prognostic significance of each mechanism in a well-characterized group of CRCLM patients.
Patients and methods
After approval by the Institutional Ethics Committee, the medical records of all consecutive patients who underwent a first resection of CRCLM during the period January 2000 to January 2010 were reviewed. Patients with repeated hepatectomies were excluded from the study. A total of 118 patients underwent a first hepatic resection for CRCLM. Patients with incomplete macroscopic resection (R2) (N = 2) and early post-operative death (within 90 days; N = 3) were excluded. The remaining 113 patients were included in this retrospective study. Intraoperative ultrasonography was employed in all patients. Liver resections were performed as previously published [14] and included non-anatomic partial hepatectomy in 16 patients, segmentectomy in 11, bisegmentectomy in 14, central hepatectomy (removal of Couinaud's segments IV, V, and VIII) in 4, right hepatectomy in 48, left hepatectomy in 14, and right trisectionectomy in 8 patients.
Pathologic evaluation
Resected specimens were submitted to conventional histological evaluation. The number of CRCLMs was determined in each patient by both pre-operative imaging and macroscopic examination of multiple slices from each resected specimen, and did not include satellite lesions according to the criteria of Taylor et al. [15] . In patients with multiple tumors, the largest tumor was chosen as representative and used for IHC staining [10, 12, 13] . Surgical margin status was histologically classified as either R0 (no residual tumor) or R1 (presence of tumor cells on the resection margin). Size of liver lesions was measured by the pathologist, in centimeters, before fixation of the specimen.
Immunohistochemistry
One to three paraffin-embedded blocks (median 1.2 blocks) from each patient were used for immunohistochemistry. After routine histopathological examination, five serial 4 lm-thick sections of each previously chosen formalinfixed paraffin-embedded tissue bloc were cut and immunohistochemically stained in a fixed order: the first section of each block was used for routine histological examination using H&E staining, the second section was used for immunohistochemical staining with D2-40 monoclonal antibody specific for lymphatic vessels (730-16, SIGNET, Cambridge, UK; dilution 1:100), the third section was used for immunohistochemical staining with CD34 polyclonal antibody for blood vessels (ab64480, Abcam, Cambridge, MA, USA; dilution 1:200), the fourth section was used for immunohistochemical staining with CK-20 monoclonal antibody [16] (monoclonal, M7019, Dako, Denmark; dilution 1:100), and the fifth section was used for immunohistochemical staining with CK-7 (monoclonal, OV-TL 12/30, Dako, Denmark; dilution 1:100).
Assessment of intrahepatic mechanisms of invasion
First, all H&E slides were screened for the presence of the four mechanisms (BVI, LVI, Bili, and SI) of intrahepatic invasion. All IHC slides were then screened using strict criteria to confirm or modify the findings obtained from H&E slides. LVI or BVI were considered positive when either single tumor cells or cell clusters were clearly visible within an endothelium-lined vessel-like structure that showed immunoreactivity for D2-40 or CD34 antibody, respectively ( Fig. 1 ) beyond the border of the studied metastasis. Perineural invasion in the resected liver was included in the category of intrahepatic lymphatic invasion as described elsewhere [10] . Bili was considered positive when either single tumor cells or cell clusters were clearly visible within an epithelium-lined structure that showed immunoreactivity for CK-7. SI was considered if discrete microscopic cancerous lesions, ranging from a single cell to clusters of cells showing immunoreactivity for CK-20 antibody, were identified within the hepatic parenchyma and separated from the invasive front of the metastasis by a rim of hepatic sinusoids. An experienced pathologist blinded to clinical details assessed each section.
Prognostic factors
Blood transfusion during or 24 h following surgery was defined as perioperative. Neoadjuvant or adjuvant chemotherapy was administered in selected cases after a multidisciplinary staff meeting. Major liver resection was defined as any resection of three or more liver segments [17] . Clinicopathologic variables studied included gender, age [ 60 years, node-positive primary cancer, liver metastases confirmed within 12 months after primary cancer resection, carcinoembryonic antigen (CEA) level C 200 ng/mL, size of metastases greater than 5 cm, bilateral hepatic metastases, and multiple ([1) metastases.
Follow-up
Patients were regularly followed with physical examination, assessment of tumor markers (CEA and carbohydrate antigen [CA] 19.9), and computed tomography or abdominal ultrasound with chest X-ray every 4-6 months. Hepatic recurrence was considered when liver metastases were present (whether solely or associated with other sites) at the first sign of disease recurrence. DFS was defined as the time interval between the date of hepatic resection and the date of the first documented recurrence at any site. OS was defined as the time interval between the date of hepatic resection and the date of death or the most recent date of follow-up if the patient was alive. The criteria for establishing recurrent disease were histologic confirmation, radiologic evidence of progression with subsequent clinical progression, and supportive biochemical data (e.g. rising serum level of CEA or CA 19.9).
Statistical analysis
The univariate associations between clinicopathologic variables and hepatic recurrence were examined using the v 2 test and/or Fisher's exact test when appropriate. Factors independently associated with hepatic recurrence were identified via multiple logistic regression analysis, which included all variables with p \ 0.1 at univariate analysis.
The risk prediction was reported as p value, odds ratio (OR) and 95 % confidence intervals (CIs).
Survival curves were constructed using the KaplanMeier method, and the differences in survival were compared using the two-tailed log rank test. The Cox proportional hazards regression model was used to identify factors that were independently associated with OS and DFS.
A two-sided p value was always computed, and a difference was considered statistically significant at p \ 0.05. Assessment of j value was used as a measure of agreement between results of H&E and IHC. Statistical analysis was performed with SPSS for Windows Ò , version 20.0 (IBM, Armonk, NY, USA).
Results
There were 64 men (57 %) and 49 women, with a mean age of 59 years (range 28-81). All patients had undergone curative resection of their primary tumor previous to the hepatic resection. Primary tumor location was the colon and rectum for 55 and 58 patients, respectively. A total of 38 patients received neoadjuvant chemotherapy prior to surgery. Seven patients had concomitant extrahepatic metastases at the time of hepatectomy: six pulmonary metastases and one localized peritoneal metastasis. In all patients with pulmonary metastases, resection was performed within 1-3 months after liver resection. Clinical and pathologic characteristics of the entire cohort are shown in Table 1 .
The mean postoperative hospital stay was 10.7 days (range 2-70). The mean follow-up after resection was 38 months (range 3-122 months). After multidisciplinary b
discussion, indication for adjuvant chemotherapy was retained for 60 patients. Tumor recurrence was observed in 76 patients (68 %), with a median interval of 13 months after resection. The overall cumulative survival rates after hepatectomy were 87, 62, and 56 % at 1, 3, and 5 years, respectively. The overall cumulative DFS rates were 49, 26, and 24 % at 1, 3, and 5 years.
Pathological results
The mean number of metastatic liver tumors was 2.2 lesions per patient (range 1-10), with 23 patients (20 %) having more than three nodules, and 48 patients (42 %) with solitary lesions. The mean size of the largest lesion was 5.3 cm (range 0.5-23.5). Resection was considered R0 in 88 % of patients. After IHC analysis, intrahepatic microscopic invasion included BVI in 49 patients, SI in 43 patients, Bili in 20 patients, and LVI in 33 patients. All intrahepatic lymphatic invasion foci were evident outside the tumor's border. Intrahepatic lymphatic invasion foci were evident within 2 mm from the metastatic liver tumor, whereas portal venous invasion were evident within 8 mm from the tumor edge. The level of agreement between H&E and IHC was excellent for BVI, SI, and Bili, but markedly lower for LVI, as shown in Table 2 .
Factors influencing hepatic recurrence, disease-free survival, and overall survival for the whole series (Table 3 ). Actuarial DFS rates according to the presence of intra-hepatic lymphatic invasion for 1, 3, and 5 years were 30 versus 56 %, 6 versus 34 %, and 6 versus 31 %, respectively (Fig. 2) .
CEA level [ 200 ng/mL was the only variable associated with OS (p = 0.003). Of note, the actuarial OS of patients presenting LVI was considerably shorter than patients without LVI (mean 85 vs. 35 months; p = 0.15) with OS rates for 3 and 5 years of 52 vs. 66 %, and 42 vs. 61 %, respectively (Fig. 2) .
Factors influencing recurrence risk, disease-free survival, and overall survival in R0 patients
In the R0 group (N = 99 patients), univariate analysis showed bilateral lesions (p = 0.028) and multiple lesions (p = 0.001) to be related to hepatic recurrence, but after multivariate logistic regression only the presence of multiple lesions was independently associated with a higher risk of hepatic recurrence (OR 3.97; p = 0.007).
DFS was associated with node-positive primary cancer (p = 0.04), multiple metastases (p = 0.007), and LVI (p = 0.008). After Cox proportional hazards regression model, multiple metastases (hazard ratio [HR] 1.89; 95 % CI 1.12-3.2; p = 0.016) and LVI (HR 1.96; 95 % CI 1.18-3.24; p = 0.009) remained independently associated with a shorter DFS in R0 patients.
Univariate analysis failed to demonstrate any significant effect of the studied variables on OS in the R0 group.
However, CEA level [ 200 ng/mL (p = 0.065) and LVI (p = 0.092) showed a trend towards shorter OS. Actuarial DFS and OS rates for 3 and 5 years in R0 patients according to the presence of LVI were 7 versus 36 %, 7 versus 33 %, and 52 versus 67 %, 41 versus 61 %, respectively.
Effect of chemotherapy in patients with LVI
The effect of preoperative chemotherapy on DFS and OS of patients presenting with LVI should also be investigated; however, as the number of patients included in this series who received preoperative chemotherapy (34 %) were limited, we were unable to provide any reliable data about this important topic. Meanwhile, the frequency of LVI in patients with (11 of 38; 28.9 %) or without (22 of 75; 29.3 %) preoperative chemotherapy was not statistically different (p = 0.827).
Among the 33 patients with confirmed LVI, 18 (55 %) had postoperative chemotherapy. Postoperative chemotherapy did not show any effect on DFS but was related to better OS (mean OS 85.3 vs. 31.2 months; p = 0.04) in this subgroup of patients with poorer outcome. On the other hand, among the 80 patients without LVI, 42 patients (52 %) had postoperative chemotherapy, which did not show any effect on DFS (p = 0.918) or OS (p = 0.520).
Discussion
This study has shown that LVI is a significant prognostic factor after surgical resection for CRCLM. It has also demonstrated that microscopic invasion of other structures (blood vessels, biliary ducts, or sinusoids), although frequently observed is not related to recurrence or survival. Recent studies support the hypothesis that lymphatic metastasis from a primary tumor site is the major pathway to progression into the systemic circulation and to distant organ sites [18] [19] [20] .
The hypothesis that blood and lymph vessel invasions are not only two different routes that cancer cells use to metastasize, but are characterized by different biological behavior is supported in our study by the fact that some patients exclusively show BVI or LVI.
The frequency and prognostic implication of hepatic pedicle lymph node invasion as the indication, extent, and therapeutic role of hilar lymphadenectomy are presently the objects of ongoing interest [21] [22] [23] [24] . Unfortunately, the retrospective character of our study did not allow us to evaluate the relationship between the presence of hilar lymph node invasion and LVI.
Tumor budding is a morphologic phenomenon observed at the advancing edge of neoplasms characterized by isolated or small clusters of tumor cells that detach from the main lesion and migrate into the neoplastic stroma [25] . In CRC, it is considered a factor of poor prognosis and has recently been the subject of increasing interest [25, 26] . SI can be considered the morphological representation of tumor budding for liver tumors, although an universally accepted definition is warranted. In our study, the presence of SI was a common phenomenon (38 %) but was unrelated to recurrence and/or survival.
The role of perioperative chemotherapy in resectable CRCLM is still a matter of debate [27] . Although postoperative chemotherapy after resection of CRCLM has become an accepted standard of care, data on its benefit are limited [27, 28] . In the present study, postoperative chemotherapy was related to a better OS in the poor prognostic group of LVI-positive patients, whereas it did not prolong DFS or OS in the LVI-negative group, thus suggesting that it might be used as a criterion in future trials dealing with adjuvant chemotherapy for CRCLM. This study is limited by its retrospective nature, the small number of patients, and the range of different anticancer agents administered to some patients. However, it raises an important subject for discussion and future investigation.
Conclusion
The current study is, to our knowledge, the largest series to date to evaluate the presence of intrahepatic lymphatic invasion using D2-40 staining [29] . It is also the first study to use specific IHC staining to assess the four most common mechanisms of intrahepatic micrometastatic dissemination (biliary, sinusoidal, lymphatic, and blood vascular). It shows that LVI rather than BVI, Bili, or SI is the key prognostic marker of aggressiveness and spread in CRCLM. Furthermore, we have demonstrated that the use of IHC staining with a lymphendothelial-specific marker (D2-40) increases the accuracy of the assessment of tumor-associated lymphatic spread and reinforce its use as part of an optimal histopathology report.
